Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.
Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, Bäsecke J, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, Ruvolo P, Ruvolo V, Evangelisti C, Martelli AM, McCubrey JA. Steelman LS, et al. Among authors: fagone p. Leukemia. 2011 Jul;25(7):1080-94. doi: 10.1038/leu.2011.66. Epub 2011 Apr 15. Leukemia. 2011. PMID: 21494257 Review.
In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells.
Donia M, Maksimovic-Ivanic D, Mijatovic S, Mojic M, Miljkovic D, Timotijevic G, Fagone P, Caponnetto S, Al-Abed Y, McCubrey J, Stosic-Grujicic S, Nicoletti F. Donia M, et al. Among authors: fagone p. Cell Cycle. 2011 Feb 1;10(3):492-9. doi: 10.4161/cc.10.3.14727. Epub 2011 Feb 1. Cell Cycle. 2011. PMID: 21270522
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.
Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino MC, Nicoletti F, Libra M, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Milella M, Tafuri A, Bonati A, Evangelisti C, Cocco L, Martelli AM, McCubrey JA. Chappell WH, et al. Among authors: fagone p. Oncotarget. 2011 Mar;2(3):135-64. doi: 10.18632/oncotarget.240. Oncotarget. 2011. PMID: 21411864 Free PMC article. Review.
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.
Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, Donia M, Fagone P, Malaponte G, Nicoletti F, Libra M, Milella M, Tafuri A, Bonati A, Bäsecke J, Cocco L, Evangelisti C, Martelli AM, Montalto G, Cervello M, McCubrey JA. Steelman LS, et al. Among authors: fagone p. Aging (Albany NY). 2011 Mar;3(3):192-222. doi: 10.18632/aging.100296. Aging (Albany NY). 2011. PMID: 21422497 Free PMC article. Review.
mTOR as a multifunctional therapeutic target in HIV infection.
Nicoletti F, Fagone P, Meroni P, McCubrey J, Bendtzen K. Nicoletti F, et al. Among authors: fagone p. Drug Discov Today. 2011 Aug;16(15-16):715-21. doi: 10.1016/j.drudis.2011.05.008. Epub 2011 May 23. Drug Discov Today. 2011. PMID: 21624501 Free article.
Therapeutic potential of nitric oxide-modified drugs in colon cancer cells.
Mojic M, Mijatovic S, Maksimovic-Ivanic D, Miljkovic D, Stosic-Grujicic S, Stankovic M, Mangano K, Travali S, Donia M, Fagone P, Zocca MB, Al-Abed Y, McCubrey JA, Nicoletti F. Mojic M, et al. Among authors: fagone p. Mol Pharmacol. 2012 Oct;82(4):700-10. doi: 10.1124/mol.112.077842. Epub 2012 Jul 13. Mol Pharmacol. 2012. PMID: 22798453
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, Candido S, Libra M, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Cocco L, Evangelisti C, Chiarini F, Martelli AM. McCubrey JA, et al. Among authors: fagone p. Oncotarget. 2012 Sep;3(9):954-87. doi: 10.18632/oncotarget.652. Oncotarget. 2012. PMID: 23006971 Free PMC article. Review.
141 results